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ABSTRACT   
 
Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid 
leukemia (CML). p21Cip1, initially described as a cell cycle inhibitor, also protects from 
apoptosis in some models. We describe that imatinib down-regulates p21Cip1 
expression in CML cells. Using cells with inducible p21 expression and transient 
transfections we found that p21 confers partial resistance to imatinib-induced 
apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease 
in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results 
suggest an involvement of p21Cip1 in the response to imatinib in CML 
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1. Introduction 
 
p21Cip1 (p21 herein after) is a member of the Cip/Kip family of inhibitors of cell 
cycle progression. The first discovered and so far best studied biochemical activity of 
p21 is to inhibit Cdks, consistent with its activity as cell cycle inhibitor [1-4]. Also, p21 is 
a relevant mediator of p53-cell cycle arrest [5-7]. However, more recent studies have 
shown that p21 has additional functions as differentiation inducer [8], transcriptional co-
regulator [9, 10] and as an inhibitor of apoptosis induced by DNA-damaging agents [11-
13]. The mechanism for p21-mediated apoptosis protection is unclear and is not 
operative in all cell types [14]. However, since cancer cells can escape death induced 
by chemotherapeutic drugs, the antiapoptotic p21 activity might be critically important 
in human cancer (reviewed in [15]). Actually, p21-null mice develop tumours 
spontaneously [16] and show increased tumour susceptibility using chemical 
carcinogenesis [17-20].  
 Imatinib is the main drug used in chronic myeloid leukemia (CML) treatment. 
The hallmark of this leukemia is the Bcr-Abl kinase, encoded by a fusion gene 
produced by the t(9;22) translocation [21, 22]. Several previous studies, including ours, 
have demonstrated that imatinib induced cell death in CML-derived cells, including 
K562 [23-25]. 
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It has been reported that imatinib down-regulates p21 in mouse cells 
transfected with Bcr-Abl [26, 27]. However, it is unknown whether imatinib regulates 
p21 expression in human CML cells and the effects of p21 in these cells. In this work 
we describe that Bcr-Abl inhibition results in low p21 levels and that ectopic p21 
expression antagonizes imatinib-mediated apoptosis, suggesting a role of p21 in the 
apoptosis response to Bcr-Abl inhibition. 
 
 
2. Materials and methods 
 
2.1 Cell culture and transfections  
 
BV173 [28], KBM5 [29], MEG01 [30] and K562 [31] cell lines derive from human 
chronic myeloid leukemia in blast crisis. Kp21-4 subline, a K562 derivative with 
inducible expression of p21 was generated as previously described [32]. The cells were 
grown in RPMI 1640 medium supplemented with 8 % fetal calf serum and antibiotics. 
Unless otherwise stated, cells at a density of 2.5 x 105cells/ml were treated with 75 µM 
ZnSO4 to induce p21 expression. Imatinib mesylate (provided by Novartis, Basel, 
Switzerland) was added one hour after ZnSO4. K562 were transiently transfected by 
nucleofection (Amaxa) following the manufacturer indications with 4,75 µg of pCEFL-
p21 [32] or empty vector and 0.25 µg of a Green Fluorescent Protein vector 
(pmaxGFP, Amaxa) to assess transfection efficiency.  
 
2.2 Proliferation, cell cycle and apoptosis assays  
Cell proliferation was assayed with a Nucleocounter (Chemometec). For cell 
cycle analysis, cells were fixed in 90% ethanol at 4ºC and resuspended in PBS-sodium 
citrate buffer containing 10 µg/ml bovine serum albumin, 200 µg/ml RNAse and 50 
µg/ml propidium iodide (Sigma). Stained cells were analyzed by flow cytometry as 
previously described [14]. Apoptosis was assessed by annexin V binding and TUNEL 
assays. Annexin V binding was detected by flow cytometry using the BD-Pharmingen 
kit. TUNEL assays were performed using In situ Cell Death Kit (Roche Applied 
Science). Apoptosis in each cell cycle phase was determined by incubating cells with 
Hoescht 33342 (Sigma) (10 µg/ml for 90 min) to stain nuclei, and then annexin V 
binding was analyzed as above. 
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2.3 RNA extraction and expression analysis 
Total RNA from cell lines and from bone marrow cells was isolated using the 
RNeasy kit (Qiagen). For reverse transcription and polymerase chain reaction (RT-
PCR), first-strand cDNA was synthesized from 1 g of total RNA using SuperScriptTM II 
RNase reverse transcriptase (Invitrogen) and random primers. Quantitative RT-PCR was 
performed as described [33] with a QuantiTectTM SYBR green PCR kit (Qiagen). The 
following primers were used: for p21 5'-AAGACCATGTGGACCTGTCA-3’ and 5’-
GGCGTTTGGAGTGGTAGAAA-3’; for ribosomal protein RPS14, 5'-
GGCAGACCGAGATGAATCCTC-3' and 5'-CAGGTCCAGGGGTCTTGGTCC-3'. For 
each gene, duplicate PCR reactions were performed on the same 96-well plate on an 
ICycler iQTM apparatus (Bio-Rad). The expression levels of p21 were normalized by the 
internal control ribosomal protein RPS14.  
 
2.4 Immunofluorescence staining, immunobloting and cellular fractionation 
Cytospin preparations were fixed with paraformaldehyde and the presence of 
p21 was detected by immunofluorescence using a rabbit polyclonal antibody (C-19 
from Santa Cruz Biotech) and Texas Red conjugated secondary antibody (Dako). Actin 
cytoskeleton was detected using phalloidin-FITC (Sigma). Samples were mounted with 
Vectashield (Vector) containing 4'-6-diamidino-2-phenylindole (DAPI) to stain nuclei 
and examined under a fluorescence microscope (Zeiss-Axioskop2). Immunoblots were 
performed as previously described [14]. Blots were revealed with the ECL system (GE 
Healthcare). Antibodies used were: anti-actin (I-19), anti-poly(ADP-ribose)polymerase 
(PARP) (H250), anti-p27 (C-19), anti-UBF (F-9), anti-RhoGDI (A-20) and anti-phospho-
tyrosine (PY20) all from Santa Cruz Biotech; anti-c-Abl from BD Pharmingen; anti-p21 
(P-184) from Sigma, and anti-α-tubulin antibody kindly provided by Nicholas Cowan 
(New York University, New York). For cellular fractionation, cells were treated in 0.1% 
paraformaldehyde in PBS during 5 min and washed with 50 mM glycine in PBS. 
Nuclear and cytoplasmic extracts were then obtained essentially as described [34] 
using 50 mM Tris, 1% Nonidet P-40, 0.2% SDS, 1 mM EDTA, 10% glycerol as nuclear 
lysis buffer. 
 
2.5. CML Patients 
Bone marrow mononuclear cells from 17 healthy individuals and from 58 CML 
patients and were studied. CML cases included 36 samples collected at the time of 
diagnosis, 7 in blast crisis and 15 in chronic phase treated with imatinib. In this case 
samples were taken up to 24 months of treatment.  The patients are from two hospitals: 
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Hospital Universitario Marqués de Valdecilla (Santander, Spain) and Hospital 
Universitario Dr. Negrín (Las Palmas, Spain). The study was approved by the ethics 
committees according to procedures approved by the two hospitals providing the 
samples. Statistical analysis was carried out with the SPSS software. 
 
  
3. Results  
We studied the expression of p21 in four CML cell lines (K562, MEG01, KBM5 
and BV173) in response to imatinib treatment. p21 levels were low although detectable 
in growing cells, and decreased upon imatinib treatment (Fig. 1A). In sharp contrast 
p27Kip1 expression, which was also very low, was unchanged or moderately up-
regulated by imatinib. p21 down-regulation by imatinib in K562 was also detected at the 
mRNA level, as assayed by qRT-PCR (Fig. 1B). We next asked whether p21 down-
regulation was involved in the cell death mediated by imatinib. To test this hypothesis 
we used a K562 subline with inducible p21 expression, termed Kp21-4 [32]. In these 
cells the expression of p21 is induced by ZnSO4 and p21 levels were dramatically 
increased 3 h after ZnSO4 addition and depended on the inducer concentration (Fig. 
1C). Next, we demonstrated that imatinib did not modify the induction of p21 by Zn2+ in 
Kp21-4 cells (Fig. 1D). In these conditions, both p21 and imatinib provoked growth 
arrest (data not shown). It is reported in many models, including K562, that p21 
induces accumulation of cells in the G2 cell cycle phase [32, 35]. We found p21 
induced G2 accumulation in the presence of imatinib after 48 h of treatment, in contrast 
to the G1 arrest mediated by imatinib alone (Fig. 1E), thus confirming that the induced 
p21 was functional in the presence of imatinib. Altogether, the results indicate that 
imatinib did not impair p21 activity on cell cycle in the K562 model. At longer times (3-5 
days) p21 induces polyploidy in K562 cells [32] but imatinib induced extensive 
apoptosis after long treatment periods [25], which precludes the analysis after long 
treatments.  
We next asked whether p21 modified the apoptosis induced by imatinib. The 
results showed that p21 significantly reduced the imatinib-mediated apoptosis. This 
was assessed by several techniques as PARP proteolysis (Fig. 2A), TUNEL assay 
(Fig. 2B) and the fraction of cells with sub-G0/G1 DNA content (Fig. 2C). The 
protection that the induction of p21 exerts against the imatinib-mediated apoptosis was 
also demonstrated by determining the binding of annexin V to cell surface (Fig. 2D). As 
p21 induced G2 phase accumulation, we asked whether cells in G2 were less sensitive 
to imatinib-mediated apoptosis. However, in double-staining experiments (Hoechst 
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33342 and annexin V) we found that the fraction of apoptotic cells was similar in the G1 
and G2 cell cycle phases (Fig. 2E). 
To confirm that p21 was indeed the responsible for the apoptosis protection we 
first performed a dose-response experiment. Different p21 levels were induced with two 
ZnSO4 concentrations (40 and 75 μM). As expected, the higher p21 levels correlated 
with a faster cell growth arrest (Fig. 3A) and with less apoptosis, as assessed by PARP 
proteolysis (Fig. 3B). The above results were obtained with the p21-inducible cell line 
Kp21-4. As this cell line was generated by selection of stable transfectants, [32] we 
wanted to rule out the possibility that the p21 effect was due to the specific behavior of 
the Kp21-4 cell line. Therefore, we transiently transfected parental K562 with an 
expression vector for p21. p21 overexpression upon transfection was confirmed by 
immunoblot (Fig. 3C). The results showed that p21-expressed cells were more 
resistant to imatinib-mediated apoptosis (Fig. 3D). Taken together, these results 
demonstrate that p21 antagonizes imatinib-induced apoptosis in K562 cells. 
It has been reported that cytoplasmic but not nuclear p21, protects leukemia 
cells from apoptosis [36]. In addition, it is reported that in murine myeloid cells 
overexpressing Bcr-Abl, p21 is predominantly cytoplasmic and imatinib treatment 
results in decreased cytoplasmic p21 expression [37]. Thus, we studied the cellular 
localization of p21 in our model of Kp21-4 cells. Immunofluorescence studies showed 
that the induced p21 was found in the nuclei and remained nuclear after imatinib 
treatment (Fig. 4A). We also carried out nucleo-cytoplasmic fractionation studies of 
Kp21-4 extracts. Immunoblot analysis showed that p21 was predominantly found in the 
nuclear compartment and that imatinib did not modify this localization (Fig. 4B). p21 
was also predominantly nuclear in untreated K562 (not shown). Finally, as imatinib-
induced apoptosis depends on Bcr-Abl inhibition we assayed the effect of p21 on Bcr-
Abl activity by determining the levels of phospho-tyrosine-Bcr-Abl. The results 
demonstrated that imatinib efficiently inhibited Bcr-Abl activity, and that the induction of 
p21 protein levels did not significantly modify this inhibition (Fig. 4C). 
Although it is known that p21 is expressed in hematopoietic precursors 
(reviewed in [38]), the expression of p21 has not been systematically analysed in CML 
patients. We asked whether p21 levels correlated with CML progression. We 
determined the expression of p21 by quantitative RT-PCR in bone marrow samples of 
36 CML patients at diagnosis, 15 in chronic phase under imatinib treatment and 7 
cases of blast crisis (the final and fatal stage of CML) [39] as well as in 17 healthy bone 
marrow samples as controls. The results indicate that the expression of p21 mRNA 
was similar in all groups (Fig. 4D). The highest expression was observed cells from 
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patients in blastic phase. However, the difference was not statistically significant (P> 
0.05). 
 
 
4. Discussion 
 
Here we show first that imatinib, the drug almost universally used in CML 
treatment, results in p21 down-regulation in human CML cells. Imatinib represses p21 
expression at the transcriptional level. The mechanism is unknown, but it is unrelated 
to p53 as three of the four cell lines tested (K562, KU812 and MEG01) do not carry 
active p53 alleles [40]. p21 gene has a complex promoter, which is regulated by many 
transcription factors [41]. Imatinib effect could be mediated by STAT5, which 
transactivates p21 [42] and is activated by Bcr-Abl [43, 44].  
It is striking that inhibition of Bcr-Abl activity results in the down-regulation of a 
protein known to stop cell cycle. However, p21 exerts apoptosis protection in many 
models [11-13]. We show here that induction of p21 protects K562 cells from imatinib-
induced apoptosis. In our model, p21 did not rescue the growth-arrest induced by 
imatinib, conversely to the result reported with mouse cells [27]. The reasons for this 
discrepancy may lie, first, in that we are using human CML cells expressing 
endogenous Bcr-Abl instead of murine cells transfected with Bcr-Abl gene, and second, 
that we use an inducible p21 gene and transient p21 transfections, rather than stable 
selected clones with high constitutive p21 expression. Given the depressing effects of 
p21 on proliferation it is likely that stable constitutive transfectants have acquired other 
epigenetic changes. 
The induced p21 remains in K562 cell nuclei in the presence of imatinib, ruling 
out in our system the described anti-apoptotic effect of cytoplasmic p21. In K562, as 
other cell models, p21 provokes the accumulation of cells in the G2 phase of the cycle, 
but imatinib did not modify this pattern. Moreover, we ruled out the hypothesis the drug 
is less active in G2 cells so as to explain p21-mediated protection. Thus, the 
mechanism for p21-mediated apoptosis protection in K562 remains unclear, as it is 
also the case in the other cell models where this effect has been observed [12, 13]. 
However, in K562 the mechanism operates downstream of Bcr-Abl inhibition as there is 
no significant change in the activity of Bcr-Abl mediated by p21. We also observed an 
increased level of p21 in cells from blastic crisis CML. This result seems consistent with 
the refractoriness of these cells to treatment with imatinib, although the difference in 
expression did not get statistical significance. Regardless of the mechanism involved, 
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our report describes for the first time the p21-mediated protection to apoptosis by the 
most used drug in CML, suggesting that p21 levels could modulate the response to the 
drug in CML treatments.  
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 Legends to Figures 
 
Fig. 1. Effects of imatinib on p21 expression in CML cells. (A) Immunoblot for p21 and 
p27, and actin as loading control, in CML-derived cell lines treated with 1 μM imatinib 
for 24 h. (B) qRT-PCR analysis showing the down-regulation of p21 mRNA in K562 
cells treated with imatinib. Data are expressed as means ± SEM. (C) Immunoblot 
analysis showing Inducible p21 expression in Kp21-4 cell line. Cells were treated with 
75 µM ZnSO4 and 0.5 µM imatinib for 3 to 48 h (left panel) or 40 and 80 μM ZnSO4 for 
6 h (right panel). (D) K562 and Kp21-4 cells were treated for 24 h with 0.5 μM imatinib 
and 75 μM ZnSO4. The blot for p21 in K562 was overexposed with respect to Kp21-4. 
(E) Cell cycle analysis of K562 and Kp21-4 cells treated for 48 h with 1 μM imatinib and 
75 μM ZnSO4. The arrow indicates the position of G2 phase and the percentage of 
cells in G2 is indicated in each case. 
 
Fig. 2. Ectopic expression of p21 confers partial resistance to imatinib-induced 
apoptosis. (A) Apoptosis was assessed by proteolytic cleavage of PARP determined by 
immunoblot in K562 and Kp21-4 cells treated with 75 µM ZnSO4 and 1 µM imatinib for 
48 h. (B) Kp21-4 cells were treated as in (A) for 24 and 48 h and TUNEL-positive cells 
were analyzed by fluorescence microscopy. Data are expressed as means ± SEM. (C) 
Kp21-4 cells were treated for 48 h as in (A). DNA content was measured by iodide 
propidium staining and flow cytometry and the fraction of cells with DNA content lower 
than 2C was scored. (D) Kp21-4 cells were treated for 48 h as in (A) and the  fraction of 
cells annexin V-positive cells was determined by flow cytometry.  Data are expressed 
as means ± SEM. (E) Cells were treated as in (A) and the apoptosis in each cell cycle 
phase was assessed by annexin V binding measured by flow cytometry. Black bars 
correspond to the fraction of annexin V positive cells, and the percentages of annexin 
V-positive cells within each cell cycle phase are indicated in each case. 
  
Fig. 3. p21 antagonizes imatinib-induced apoptosis. (A) Cell proliferation analysis of 
Kp21-4 cells treated for 48h with 1 μM imatinib and 40 or 75 μM ZnSO4. (B) Apoptosis 
of Kp21-4 cells assessed by PARP proteolysis in cells treated for 24 h with 1 μM 
imatinib and 40 or 75 μM ZnSO4. (C) Expression of p21 in K562 cells nucleofected with 
a p21 expression vector. Cell lysates were prepared 24 h after nucleofection and 
analyzed by immunoblot. (D) Apoptosis assessed by cytometry in K562 transfected 
with p21. Imatinib (1 μM) was added 24 h after transfection and cells were further 
incubated for 24 h. Data are expressed as means ± SEM. 
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Fig. 4. Nuclear localization of p21 (A) p21 subcellular localization in Kp21-4 cells 
treated for 24 h with 75 µM ZnSO4 and 1 µM imatinib. Cytospin preparations were 
subjected to immunofluorescence with anti-p21 and stained with phalloidin-FITC and 
DAPI to visualize cytoskeleton and nuclei, respectively. (B) Cellular fractionation of 
Kp21-4. Extracts from nuclear and cytoplasmic fraction were analyzed by immunoblot 
with anti-p21, anti-UBF (nuclear fraction control) and anti-RhoGDI (cytoplasmatic 
fraction control). (C) Inhibition of Bcr-Abl activity as determined by phospho-tyrosine-
Bcr-Abl. Extracts of K562 and Kp21-4 cells were treated as in (A) and subjected to 
immunoblot using the antibodies against Bcr-Abl, c-Abl, p21, actin and phospho-
tyrosine. The blot for p21 in K562 was overexposed with respect to Kp21-4. (D) p21 
mRNA expression assayed by qRT-PCR in samples from CML patients at different 
stages of the disease. p21 mRNA levels were normalized with RPS14 expression. 
Each box refers to the range defined by the 25th and the 75th percentiles and the line 
indicates the median value. HC, healthy controls; CP-Dg, chronic phase at diagnosis; 
CP-Im, chronic phase treated with imatinib; BC, blastic crisis. In all comparisons the 
differences were not significant (P > 0.05).  
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